How to buy IVERIC bio stock (ISEE)

IVERIC bio is a biotechnology & medical research business based in the US. IVERIC bio shares (ISEE) are listed on the NASDAQ and all prices are listed in US Dollars. IVERIC bio employs 163 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy IVERIC bio stock

Buy IVERIC bio stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

IVERIC bio stock price (NASDAQ: ISEE)

Use our graph to track the performance of ISEE stocks over time.

IVERIC bio shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$38.32
200-day moving average more info button	$26.70
Wall St. target price	$38.20
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.78

Is it a good time to buy IVERIC bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IVERIC bio financials

Gross profit TTM	$-117,012,000
Return on assets TTM	-29.64%
Return on equity TTM	-55.02%
Profit margin	0%
Book value	$3.48
Market Capitalization more info button	$5.5 billion

TTM: trailing 12 months

IVERIC bio share dividends

We're not expecting IVERIC bio to pay a dividend over the next 12 months.

IVERIC bio share price volatility

Over the last 12 months, IVERIC bio's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IVERIC bio's is 1.1035. This would suggest that IVERIC bio's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

IVERIC bio overview

IVERIC bio, Inc. , a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc.

Frequently asked questions

What percentage of IVERIC bio is owned by insiders or institutions?
Currently 0.658% of IVERIC bio shares are held by insiders and 109.364% by institutions. How many people work for IVERIC bio?
Latest data suggests 163 work at IVERIC bio. When does the fiscal year end for IVERIC bio?
IVERIC bio's fiscal year ends in December. Where is IVERIC bio based?
IVERIC bio's address is: 8 Sylvan Way, Parsippany, NJ, United States, 07054 What is IVERIC bio's ISIN number?
IVERIC bio's international securities identification number is: US46583P1021 What is IVERIC bio's CUSIP number?
IVERIC bio's Committee on Uniform Securities Identification Procedures number is: 46583P102